Impact of PEGylation on an antibody-loaded nanoparticle-based drug delivery system for the treatment of inflammatory bowel disease

Shrestha, Neha; Xu, Yining; Prévost, Julien R. C.; McCartney, Fiona; Brayden, David J.; Frédérick, Raphaël; Beloqui, Ana; Préat, Véronique

doi:10.1016/j.actbio.2021.12.015

Cited by 17 publications

(6 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PLGA particle functionalization with other polymers can be achieved in a similar way using PEG. A study by Shrestha et al demonstrated that even the PEG chain length affects the in vivo penetrating performance of NPs, likely due to the change in hydrophilicity according to the polymer length [ 101 ].…”

Section: Inflammatory Bowel Diseasementioning

confidence: 99%

Use of Poly Lactic-co-glycolic Acid Nano and Micro Particles in the Delivery of Drugs Modulating Different Phases of Inflammation

et al. 2023

View full text Add to dashboard Cite

Chronic inflammation contributes to the pathogenesis of many diseases, including apparently unrelated conditions such as metabolic disorders, cardiovascular diseases, neurodegenerative diseases, osteoporosis, and tumors, but the use of conventional anti-inflammatory drugs to treat these diseases is generally not very effective given their adverse effects. In addition, some alternative anti-inflammatory medications, such as many natural compounds, have scarce solubility and stability, which are associated with low bioavailability. Therefore, encapsulation within nanoparticles (NPs) may represent an effective strategy to enhance the pharmacological properties of these bioactive molecules, and poly lactic-co-glycolic acid (PLGA) NPs have been widely used because of their high biocompatibility and biodegradability and possibility to finely tune erosion time, hydrophilic/hydrophobic nature, and mechanical properties by acting on the polymer’s composition and preparation technique. Many studies have been focused on the use of PLGA-NPs to deliver immunosuppressive treatments for autoimmune and allergic diseases or to elicit protective immune responses, such as in vaccination and cancer immunotherapy. By contrast, this review is focused on the use of PLGA NPs in preclinical in vivo models of other diseases in which a key role is played by chronic inflammation or unbalance between the protective and reparative phases of inflammation, with a particular focus on intestinal bowel disease; cardiovascular, neurodegenerative, osteoarticular, and ocular diseases; and wound healing.

show abstract

Section: Inflammatory Bowel Diseasementioning

confidence: 99%

Use of Poly Lactic-co-glycolic Acid Nano and Micro Particles in the Delivery of Drugs Modulating Different Phases of Inflammation

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Tgt-NP-Met was formulated according to a previously described procedure with modification. 16 Briefly, PLGA-PEG-MAL polymers (Mitachieve, China) and netrin-1 mAbs (Abcam, UK) or IgG mAbs (used as control; Abcam, UK) were mixed (1:1 molar ratio) in phosphate buffer solution (PBS) and then gently stirred at room temperature for 24 h. mAbconjugated PLGA-PEG-MAL polymers were collected via centrifugation (12,000 rpm for 15 min). To form metforminloaded NPs, metformin and mAb-conjugated PLGA-PEG-MAL polymers (1:1 w/w) were dissolved in acetone.…”

Section: Synthesis and Characterization Of Metformin-loaded Targeting...mentioning

confidence: 99%

Netrin-1 Monoclonal Antibody-Functionalized Nanoparticle Loaded with Metformin Prevents the Progression of Abdominal Aortic Aneurysms

Zhang¹,

Zhuang²,

Sun³

et al. 2023

IJN

View full text Add to dashboard Cite

Background: Abdominal aortic aneurysms (AAAs) are a global health and economic burden. Therapeutic strategies to inhibit the progression of AAAs are currently lacking. Recently, the therapeutic effect of metformin on aneurysms has attracted considerable interest. However, the unfavorable pharmacokinetic properties of metformin limit its feasibility for AAA treatment. Methods and Results:We constructed a metformin-loaded netrin-1-responsive AAA-targeted nanoparticle (Tgt-NP-Met) for AAA management. Evaluation of the therapeutic effect of Tgt-NP-Met was performed by in vitro and in vivo experiments. Our results showed that the binding of netrin-1 monoclonal antibodies enhanced the AAA-targeting capability of nanoparticles (NPs). Moreover, Tgt-NP-Met administration prevented AAA development and reduced the aneurysm diameter in apolipoprotein E (ApoE)-deficient (ApoE −/− ) mice that received continuous infusion of angiotensin II. Furthermore, metformin prevented AAA progression by inhibiting the transformation of vascular smooth muscle cells (VSMCs) from a contractile phenotype to a synthetic phenotype, which is mediated by macrophage infiltration and activation. Conclusion: Our findings identify metformin as a functional suppressor for macrophage-mediated phenotypic transformation of VSMCs and Tgt-NP-Met as an efficient therapeutic strategy for AAA management.

show abstract

“…Nanoparticles (NPs) are extraordinarily potential vehicles as colon-targeted DDSs in IBD therapy due to their small size, large surface area, shape modulation and high surface functionality. 63–66 Meanwhile, NPs possess with preferable stability to protect encapsulated agents against harsh biological environments in the GI tract, such as low pH and enzyme degradation. 67,68 Therefore, several researchers have been devoted to engineering suitable NPs as colon-targeted DDSs for IBD treatment in the past years.…”

Section: Np Systemsmentioning

confidence: 99%

Nanoparticles for oral delivery: targeted therapy for inflammatory bowel disease

Yang

et al. 2022

J. Mater. Chem. B

View full text Add to dashboard Cite

show abstract

Impact of PEGylation on an antibody-loaded nanoparticle-based drug delivery system for the treatment of inflammatory bowel disease

Cited by 17 publications

References 48 publications

Use of Poly Lactic-co-glycolic Acid Nano and Micro Particles in the Delivery of Drugs Modulating Different Phases of Inflammation

Use of Poly Lactic-co-glycolic Acid Nano and Micro Particles in the Delivery of Drugs Modulating Different Phases of Inflammation

Netrin-1 Monoclonal Antibody-Functionalized Nanoparticle Loaded with Metformin Prevents the Progression of Abdominal Aortic Aneurysms

Nanoparticles for oral delivery: targeted therapy for inflammatory bowel disease

Contact Info

Product

Resources

About